Cogent Biosciences (COGT) Current Assets (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Current Assets of $877.8 million for Q1 2026, up 247.12% year-over-year from $252.9 million in Q1 2025, and down 3.58% quarter-over-quarter from $910.4 million in Q4 2025.
Cogent Biosciences (COGT) Current Assets (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Current Assets for 10 consecutive years, with $877.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 247.12% year-over-year to $877.8 million; the TTM figure through Mar 2026 stood at $877.8 million (up 247.12% YoY), while the FY2025 annual figure was $910.4 million, up 207.06% from the prior year.
- Current Assets declined to $877.8 million in Q1 2026 per COGT's latest filing, from $910.4 million in the prior quarter.
- Across five years, Current Assets topped out at $910.4 million in Q4 2025 and bottomed at $194.7 million in Q1 2022.
- Historically, Current Assets has averaged $372.8 million across 5 years, with a median of $296.5 million in 2024.
- Annual changes were most pronounced in 2025 — Current Assets sank 42.77% — and 2026, when it surged 247.12%.
- Cogent Biosciences' Current Assets stood at $265.0 million in 2022, then increased by 2.19% to $270.8 million in 2023, then advanced by 9.49% to $296.5 million in 2024, then soared by 207.06% to $910.4 million in 2025, then slipped by 3.58% to $877.8 million in 2026.
- Business Quant data shows COGT's Current Assets at $877.8 million in Q1 2026, $910.4 million in Q4 2025, and $397.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 804.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 804.82 Mn |
| Mar 31, 2026 | 877.80 Mn |
| Dec 31, 2025 | 910.36 Mn |
| Sep 30, 2025 | 397.24 Mn |
| Jun 30, 2025 | 245.01 Mn |
| Mar 31, 2025 | 252.88 Mn |
| Dec 31, 2024 | 296.47 Mn |
| Sep 30, 2024 | 341.53 Mn |
| Jun 30, 2024 | 369.97 Mn |
| Mar 31, 2024 | 441.90 Mn |
| Dec 31, 2023 | 270.77 Mn |
| Sep 30, 2023 | 285.95 Mn |
| Jun 30, 2023 | 334.52 Mn |
| Mar 31, 2023 | 226.27 Mn |
| Dec 31, 2022 | 264.97 Mn |
| Sep 30, 2022 | 296.42 Mn |
| Jun 30, 2022 | 330.68 Mn |
| Mar 31, 2022 | 194.73 Mn |
| Dec 31, 2021 | 222.63 Mn |
| Sep 30, 2021 | 207.50 Mn |